tiprankstipranks
Trending News
More News >

Opko Health initiated with a Neutral at JPMorgan

JPMorgan initiated coverage of Opko Health (OPK) with a Neutral rating and no price target Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue